Edgewise Therapeutics (Nasdaq: EWTX) has completed the sale of sevasemten and its muscular dystrophy business to Servier, an independent international ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE